-
Current guidelines recommend mitral-valve surgery for severe organic mitral regurgitation in asymptomatic patients if exercise pulmonary hypertension (PASP > 60 mmHg) is demonstrated.
-
-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
Platelet aggregation is an important pathophysiological step in the development of myocardial infarction (MI), and intensive anti-platelet therapy has become a cornerstone of therapy in patients presenting with MI.
-
The wearable cardioverter-defibrillator (WCD) is a totally external system that can monitor a patient's cardiac rhythm and automatically treat episodes of ventricular tachycardia (VT) and ventricular fibrillation (VF) when they are detected.
-
Dual-antiplatelet therapy with aspirin and clopidogrel is recommended for patients with known vascular disease or multiple risk factors for vascular disease. However, little is known about the long-term bleeding risk of such therapy.
-
-
Access-site bleeding is one of the major complications of percutaneous coronary intervention (PCI). It is associated with the need for blood transfusions, increased length of stay, and increased healthcare expenditure.
-
The can rapid-risk stratification of unstable angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) is a registry study of acute coronary-syndrome patients.
-
Many patients who receive pacemakers or implantable cardioverter defibrillators (ICDs) are chronically treated with antiplatelet agents, warfarin, or a combination of the two. In this paper, Tompkins and colleagues from the Johns Hopkins Hospital report the results of a retrospective review of antiplatelet and anticoagulant management in patients receiving cardiac-rhythm devices.
